Revenio is a successful, globally operating health technology corporation.
The focus of Revenio’s screening technology is on the early detection of Glaucoma, Diabetic Retinopathy and Macular Degeneration, and the monitoring of these diseases during the treatment process. Revenio Research in turn focuses on the commercialization of systems designed to help diagnose and plan the treatments for skin cancer and asthma.
Revenio Group's core business is to develop and commercialize efficient and easily adopted health tech devices especially for the detection of eye diseases that are significant to public health. The amount of eye diseases is rising rapidly due to the aging of the population.
The common denominators of Revenio’s business operations include patient-driven screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology.
Revenio's strong expertise in technology, strict quality criteria throughout the supply chain, and an understanding of different markets provide a strong basis for the company to be a global leader in healthtech-related screening devices in the future as well.
Continuous investment in research and product development will open up new opportunities for the Group and strengthen the market position of our existing products.
Global leader in eye diagnostics
Revenio is a leading global player in ophthalmic products related to eye diagnostics. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Icare USA inc., Centervue SpA, Centervue Inc. and Revenio Research Oy.
We strive to improve the efficiency of eye diagnosis globally by providing unique and user-friendly solutions for healthcare professionals and patients.
A pioneer in its business
Our vision is to be the provider of choice for unique healthcare solutions for our customers and partners.
We enable our customers easy and efficient eye diagnostics. Our position as a global player in ophthalmic equipment is strong, which means our customers reliability and ability to buy all important modern products for the treatment of eye diseases.
We aspire to improve efficiency in diagnosis worldwide by providing unique and user-friendly solutions to healthcare professionals and patients.
Our goal is to strengthen our position as a global market leader in eye related diseases, especially in Glaucoma, related diagnostics and monitoring products. We will expand our foundation and market reach with new product offering and knowledge in new applications and breakthrough technologies.
Our people, network of experts, uncompromising commitment to quality and competitive products are the cornerstones for continued growth. We build our success through strong branding & IPR, unique products, top-quality, world-class operations and selling through best channels & partners.
Health care is facing unprecedented global challenges. At the same time, the need for cost-effective health care is increasing. Innovations that enhance preventive health care and are easily available everywhere in the world increase the accessibility, quality, and productivity of health care. Revenio’s objective is to become a leading global health technology company specializing in patient-led screening. In the field of preventive and cost-effective healthcare, the importance of patient-oriented screening is increasing with the aging population and with lesser national resources. What the health care sector needs is innovations that increase the quality and productivity of healthcare and that are easy to use and can be adopted worldwide at low cost. In this development Revenio wants to be a pioneer in its business.
Our vision is to be the provider of choice for unique healtcare solutions.
Our mission is to contribute better quality of life with our healthcare solutions enabling improved diagnosis.
Our values are
Trust & Integrity
People & Teamwork
Innovation & Quality
Growth & Value creation
Revenio Group Corporation Corporate Governance structure
The Revenio Group comprises the parent company Revenio Group Corporation and its wholly or partly owned subsidiaries Icare Finland Oy, Icare USA Inc., CenterVue SpA, Centervue Inc, Revenio Research Oy and Oscare Medical Oy.
The main product and the core business of Icare Finland are Icare tonometers for the measurement and monitoring of glaucoma.
CenterVue SpA, a company acquired by Revenio (Revenio Italy S.R.L) in April of 2019, is a global company, that develops, produces, and sells high-technological diagnostics systems for the early detection and management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration.
Revenio Research focuses on health technology R&D projects with the aim of commercializing new solutions for healthcare professionals. The common denominator of the projects is to support the planning of diagnosis and treatment in common serious illnesses.
Oscare Medical is developing and marketing a small and lightweight device for measuring bone strength and identifying people with an elevated risk of osteoporosis.